Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Buchanan

Showing results (291-300 of 303) with videos related to

Pageof 31
Sort By:
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature Chemical Biology|August 31, 2017
Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complexYupeng He, Sujatha Selvaraju, Michael L Curtin, et al.
Nature Chemical Biology|January 31, 2017
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complexYupeng He, Sujatha Selvaraju, Michael L Curtin, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Proteins|July 16, 2005
Structural analysis of a set of proteins resulting from a bacterial genomics projectJ Badger, J M Sauder, J M Adams, et al.
Pageof 31

Showing results (291-300 of 303) with videos related to

Sort By:
Pageof 31
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature Chemical Biology|August 31, 2017
Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complexYupeng He, Sujatha Selvaraju, Michael L Curtin, et al.
Nature Chemical Biology|January 31, 2017
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complexYupeng He, Sujatha Selvaraju, Michael L Curtin, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Proteins|July 16, 2005
Structural analysis of a set of proteins resulting from a bacterial genomics projectJ Badger, J M Sauder, J M Adams, et al.
Pageof 31